Beckley Psytech
4 known investors
AtaiBeckley develops rapid-acting and durable mental health treatments for patients with difficult-to-treat mental health conditions. The company was founded in 2025 following a strategic combination of atai Life Sciences and Beckley Psytech.
BiotechMedical DevicesMental Health
Founders & leadership
CA
Christian Angermayer
SR
Srinivas Rao
Investors · 4
In the news
- Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal | 1470 & 100.3 WMBDwmbdradio.com · 2026
- atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapiesglobenewswire.com · 2025
- AtaiBeckley (NASDAQ: ATAI) finalizes all-share deal; funding expected into 2029stocktitan.net · 2025
- Beckley Psytech Raises $80 Million to Develop Portfolio of Psychedelic Medicines - Global Genesglobalgenes.org · 2021
- Beckley Psytech raises £58m to advance psychedelic medicines pipeline - PharmaTimespharmatimes.com · 2021
- UK-based Beckley Psytech raises £14 million to advance drug discovery to clinical trials - Tech.eutech.eu · 2020